Search Results for: ATIC

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CIP2A cellular inhibitor of PP2A
Novel CPS1 carbamoyl-phosphate synthase 1
  • Urea cycle
  • Carglumic acid
  • Carbamoyl phosphate synthetase I deficiency
Novel DES desmin
  • Striated Muscle Contraction
  • Distal muscular dystrophies, including: Welander distal myopathy (WDM); Tibial muscular dystrophy (TMD); Nonaka distal myopathy with rimmed vacuoles (DMRV); Miyoshi myopathy (MM); Laing myopathy (MPD1); Distal nebulin myopathy (DNM); Distal desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Distal myotilinopathy (MFM3); Distal zaspopathy (MFM4); Distal myopathy 3 (MPD2, VCPDM)
  • Myofibrillar myopathies (MFM), including: Desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Myotilinopathy (MFM3); Zaspopathy (MFM4); Filaminopathy (MFM5); Bag3opathy
  • Scapuloperoneal myopathy (SPM)
  • Dilated cardiomyopathy (DCM)
Novel MAP3K7 mitogen-activated protein kinase kinase kinase 7
  • Activation of NF-kappaB in B cells
  • NOD1/2 Signaling Pathway
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • Ca2+ pathway
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • TNFR1-induced NFkappaB signaling pathway
  • CLEC7A (Dectin-1) signaling
  • Ub-specific processing proteases
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Interleukin-1 signaling
  • IRAK2 mediated activation of TAK1 complex
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • Alpha-protein kinase 1 signaling pathway
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
Novel VWC2L von Willebrand factor C domain containing 2 like
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
LINC01554 long intergenic non-protein coding RNA 1554
MTNR1A melatonin receptor 1A
  • Class A/1 (Rhodopsin-like receptors)
  • G alpha (i) signalling events
  • Ramelteon
  • Melatonin
  • Resveratrol
  • Agomelatine
  • Tasimelteon
PRNP prion protein
  • NCAM1 interactions
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Tetracycline
  • Copper
  • Prion diseases; Creutzfeldt-Jacob disease (CJD); Gerstmann-Straussler disease (GSD); Gerstmann-Straussler-Scheinker disease (GSSD); Fatal familial insomnia (FFI)
SERPINB5 serpin family B member 5
  • S,S-(2-Hydroxyethyl)Thiocysteine

Page 1 out of 1 pages